ISRCTN23263504
Completed
Not Applicable
A pilot study to assess the safety and efficacy of the Transcend CyPass glaucoma implant in patients with open angle glaucoma who have failed medical treatment
Transcend Medical, Inc.™ (USA)0 sites20 target enrollmentJune 17, 2010
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Primary open angle glaucoma
- Sponsor
- Transcend Medical, Inc.™ (USA)
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Males or females 18 years of age or older
- •2\. Diagnosis in the study eye of primary open angle glaucoma (POAG) or open angle glaucoma associated with pseudoexfoliation syndrome or pigmentary glaucoma
- •3\. Patients able to understand the requirements of the study and willing to follow study instructions, to provide written informed consent to participate, and who agree to comply with all study requirements, including the required study follow\-up visits
- •4\. Intra\-ocular pressure (IOP) of greater than or equal to 21 mmHg and less than or equal to 40 mmHg while on maximal tolerated medical therapy, documented at two sequential visits at any time of day, at least 48 hours apart, within 45 days prior to surgery
- •5\. Patients must sign and witness the current Informed Consent Document
- •6\. Patients must have sufficient space of the angle to accommodate the device
Exclusion Criteria
- •1\. Visual acuity of light perception or less in the study eye
- •2\. Any previous surgery for any aqueous shunt device
- •3\. Prior laser treatment of the retina
- •4\. Any ophthalmic surgery performed within three months prior to study
- •5\. Diagnosis of angle closure following penetrating keratoplasty, neovascular glaucoma, congenital glaucoma, developmental glaucoma, previous goniotomy, active uveitis within six months, or other secondary glaucomas (except pseudoexfoliation syndrome or pigmentary glaucoma, which are allowed)
- •6\. Best corrected visual acuity (BCVA) less than 20/200 in the fellow eye
- •7\. Active diabetic retinopathy
- •8\. Clinically significant inflammation or infection within six months prior to study
- •9\. Uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) in the opinion of the Investigator
- •10\. Participation in any study involving an investigational drug within the past 45 calendar days, or ongoing participation in a study with an investigational device
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Transcend CyPass glaucoma implant and cataract surgery in open angle glaucoma patientsISRCTN86839890Transcend Medical, Inc.™ (USA)20
Active, not recruiting
Not Applicable
A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemiaon Familial Chylomicronemia Syndrome (Non-FCS)MedDRA version: 14.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Non Familial Chylomicronemia Syndrome (Non-FCS)EUCTR2012-000872-40-CZovartis Pharma Services AG60
Completed
Phase 3
A pilot study to assess the efficacy and safety of Heliox inhalation therapy for resuscitation to preterm infants.preterm infantsJPRN-UMIN000015061agano Children's Hospital10
Active, not recruiting
Phase 1
A preliminary study to assess if low dose iron is safe and effective in patients with inflammatory bowel diseaseIron deficiency anaemia in inflammatory bowel diseaseMedDRA version: 20.0Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 100000004851MedDRA version: 20.1Level: PTClassification code 10021972Term: Inflammatory bowel diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2018-002982-20-GBRoyal Liverpool University Hospital30
Completed
Not Applicable
Pilot Study Evaluating the efficacy and safety of Polymyxin B-immobilized Fiber Column (PMX) Hemoperfusion Treatment for Idiopathic Pulmonary Fibrosis with Acute ExacerbatioJPRN-UMIN000013116ippon Medical School Hospital20